IN RESPONSE:
We oppose the recommendation of Otero and Schmitt and others to exclude events related to error from the definition of adverse drug reactions. Doing so would significantly alter the meaning of a term used for decades by the pharmacovigilance community, including regulatory agencies worldwide. Adoption of these new definitions would force agencies to revise regulations and would diminish capacity to analyze trends in rates of adverse drug reactions. The additional complexity of classification also risks exacerbating underreporting of adverse drug reactions by clinicians.
The distinction proposed by Otero and Schmitt and others has logical flaws. Regardless of whether an error is judged to be present, harm due to a drug is always caused in part by the drug's intrinsic properties. Stipulating lack of preventability as central to the definition of adverse drug reactions also tends to increase rather than decrease confusion. One problem with defining error and preventability as exactly equivalent is that not all errors are preventable, given the intrinsic limitations of human-designed systems and behav- Letters iors. Furthermore, as human errors are conceptualized in current scientific and ethical contexts, many reactions that are currently judged to be unavoidable or acceptable may later be found to be avoidable, unacceptable, or both. The exclusive focus on error, moreover, deflects attention from the larger number of adverse drug reactions that may be preventable but not due to error.
We acknowledge the structural similarity between the figure used in our paper and the one previously published by the American Society of Health-System Pharmacists. However, there are key differences in interpretation and meaning.
Jonathan R. Nebeker 
Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction
TO THE EDITOR: Pilote and colleagues (1) presented data suggesting that ramipril was superior to other angiotensin-converting enzyme (ACE) inhibitors after myocardial infarction. Their carefully discussed methods, in concert with the accompanying outstanding editorial (2), should confer the overall message that the study's design and limitations render its findings no more than hypothesis-generating. The authors rightfully pointed out that the distribution of observed mortality differences among the 7 ACE inhibitors studied is not consistent with any known pharmacologic property of these agents (that is, ACE inhibitors with higher tissue affinity did not consistently fare better than those with low tissue affinity). In addition, the editorial noted that mortality differences among ACE inhibitors in Pilote and colleagues' analysis were larger than those between ACE inhibitors and placebo in randomized trials (raising significant concerns about the validity of their data). In addition, ␤-blocker and statin use was substantially higher in patients receiving ramipril. Therefore, the conclusion that "survival benefits . . . seem to differ according to the specific ACE inhibitor prescribed" seems somewhat premature, much like the similar content of the take-home message in the Summary for Patients (3).
My colleagues and I recently completed what is, to our knowledge, the first randomized, double-blind study in patients with congestive heart failure (CHF) comparing effects of long-term therapy with low versus high tissue affinity ACE inhibitors on endothelial function, exercise capacity, and neurohormonal profiles (4). We did not detect any differences. In the absence of positive results from trials performing large-scale head-to-head comparisons of ACE inhibitors, the available evidence, including the recent Valsartan in Acute Myocardial Infarction (VALIANT) trial, strongly suggests that no clinically relevant differences exist among agents blocking the renin-angiotensin system. This is a reassuring message for our patients.
Ulrich Jorde, MD
New York University School of Medicine New York, NY 10016 TO THE EDITOR: Although a difference in effect of ACE inhibitors cannot be excluded, the improved survival reported by Pilote and colleagues (1) with ramipril compared with other agents might be alternatively explained by the higher rates of statin and ␤-blocker use in the ramipril group. The accompanying editorial (2) noted these higher rates, although not as a possible cause of Pilote and colleagues' results.
According to Pilote and colleagues' data, ACE inhibitors with best to worst survival rates were ramipril, perindopril, lisinopril, enalapril, quinapril, fosinopril, and captopril. Statin use in these groups was 39.2%, 37%, 30.5%, 21.4%, 26.9%, and 14.7%, respectively, and ␤-blocker use was 70.8%, 70%, 56.7%, 52.6%, 55.4%, 54.3%, and 45.6%, respectively. Given that both statins and ␤-blockers improve survival after myocardial infarction, it is likely that the differences in survival, which relatively paralleled the differences in both ␤-blocker and statin use, were due not to differences in the ACE inhibitors but to the concomitant medical therapy.
Heather L. Horton, MD, PhD
Scranton, PA 18507 for the risk reduction seen with ramipril versus other drugs in our study do overlap with the 95% CIs for ramipril versus placebo in the Heart Outcomes Prevention Evaluation (HOPE) (2) and the Acute Infarction Ramipril Efficacy (AIRE) trial (3) . Accordingly, to argue that we reported higher risk reductions between ACE inhibitors than between ramipril and placebo would amount to ignoring the role of sampling error.
The editorial by Drs. Hennessy and Kimmel also suggested that our results might have been confounded by the severity of CHF, even if we did adjust for the presence or absence of any CHF at baseline (1). Fortunately, we were able to empirically test Drs. Hennessy and Kimmel's conjecture. It posits that by pure logic the impact of CHF on mortality would have to be much weaker in the ramipril group than among users of other ACE inhibitors, implying the CHF-by-drugs interactions. We added 6 such interactions to the multivariable model in our Table 3 . All of the interactions were statistically nonsignificant (all P values Ͼ 0.18), clearly showing that the observed better survival of ramipril users cannot be due to confounding by the unknown severity of CHF.
Dr. Jorde refers to an unpublished study that investigates outcomes such as endothelial function rather than death. This trial, unlike ours, is not a head-to-head comparison of ACE inhibitors. Similarly, the VALIANT trial (4) did not compare different ACE inhibitors but an ACE inhibitor with an angiotensin II blocker. One should be cautious about generalizing results on intermediate outcomes to mortality and about generalizing a similar effect to all agents blocking the renin-angiotensin system. Drs. Horton, Jorde, Kimmel, and Hennessy are concerned that the higher rate of use of ␤-blockers and statins in the ramipril group could explain the apparent survival advantage associated with ramipril. However, all of these authors overlooked the fact that we did adjust for these differences, as can be seen in our Table 3 . The results show that the lower mortality rates in the ramipril group are independent of statins and ␤-blockers.
